Status:
NOT_YET_RECRUITING
Application of Indocyanine Green Tracer in D2 Lymphadenectomy of Locally Advanced Gastric Cancer
Lead Sponsor:
Hospital of Navarra
Conditions:
GASTRIC CANCER
Indocyanine Green (ICG)
Eligibility:
All Genders
18-85 years
Phase:
NA
Brief Summary
Gastric cancer is a frequent neoplasm in the world, presenting more than one million new cases and around 768,000 deaths in the data registered in 2020. Among the therapeutic options for gastric cance...
Detailed Description
Objective: \- Mean total number of nodes/ nodal ratio (number of positive nodes divided by the number of total nodes). Secondary objective: * Overall Survival and disease- free survival at 2 and 5 ...
Eligibility Criteria
Inclusion
- T2-T4a, N+, M0 on preoperative study
- PS 0-1
- ASA I-III
- Laparoscopic surgery
Exclusion
- \- Previous gastric abdominal surgery
- DSE
- Cognitive impairment
- Allergic to iodine
- Synchronous neoplasm
- Stroke in the last 6 months
- Angina or AMI in the last 6 months
- Plastic lymphitis
- Open surgery
Key Trial Info
Start Date :
March 1 2026
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2032
Estimated Enrollment :
102 Patients enrolled
Trial Details
Trial ID
NCT06892392
Start Date
March 1 2026
End Date
December 1 2032
Last Update
March 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Universitario de Navarra
Pamplona, Navarre, Spain, 310013